Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Memphasys's gross profit for the
six
months ended in Dec. 2025 was A$0.01 Mil. Memphasys's gross profit for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.03 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Memphasys's gross profit for the
six
months ended in Dec. 2025 was A$0.01 Mil. Memphasys's Revenue for the
six
months ended in Dec. 2025 was A$0.01 Mil. Therefore, Memphasys's Gross Margin % for the quarter that ended in Dec. 2025 was 50.00%.
Memphasys had a gross margin of 50.00% for the quarter that ended in Dec. 2025 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of Memphasys was 60.00%. The lowest was -900.00%. And the median was 16.48%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Memphasys had a gross margin of 50.00% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Memphasys Gross Profit Related Terms
Memphasys Gross Profit Historical Data
* Premium members only.
The historical data trend for Memphasys's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Memphasys's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Memphasys Gross Profit vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Memphasys's Gross Profit distribution charts can be found below:
* The bar in red indicates where Memphasys's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.03 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Memphasys (ASX:MEM) has a Gross Profit of A$-0.03 Mil as of Dec. 2025. Gross Profit equals net sales less total cost of goods sold. View historical data on Memphasys and its competitors.
Is Memphasys' Gross Profit too high?
Memphasys' current Gross Profit is A$-0.03 Mil.
How does Memphasys' Gross Profit compare to ABT and SYK?
Memphasys' Gross Profit of A$-0.03 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Devices & Instruments company?
A good Gross Profit depends on the Medical Devices & Instruments industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Memphasys and its competitors. Memphasys's current Gross Profit is A$-0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Memphasys stock overvalued right now?
Memphasys (ASX:MEM) has a current Gross Profit of A$-0.03 Mil. The current Gross Profit is A$-0.03 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Memphasys (ASX:MEM), the current Gross Profit is A$-0.03 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Memphasys Ltd is an Australian reproductive biotechnology company developing and commercializing novel reproduction and fertility solutions for humans and animals. The products in its development pipeline include a range of devices, media, and in vitro diagnostic solutions. The company is currently focused on the commercialisation of its patented Felix System, a novel bio-separation technology for assisted reproduction, designed to revolutionise sperm separation in assisted reproductive technology (ART) by providing a rapid, gentle, and automated process. The group has only one operating segment, being Reproductive Technologies, the assets and liabilities of which are located in Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MEM has been successfully added to your 
